icon-folder.gif   Conference Reports for NATAP  
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
Barcelona, Spain
13-17 April 2016
Back grey_arrow_rt.gif
On-Treatment Illicit Drug Use Did Not Impact Treatment Outcome During Therapy With Ledipasvir/Sofosbuvir With or Without Ribavirin in the Phase 3 ION-1 Study
  Reported by Jules Levin
EASL 2016 April 14-7 Barcelona
Jason Grebely,1 Steve Flamm,2 Stefan Zeuzem,3 Robert H. Hyland,4 Paul Chang,4 Yanni Zhu,4 Chohee Yun,4 Diana M. Brainard,4 John G. McHutchison,4 Xavier Forns,5 Alessandra Mangia,6 Gregory J. Dore1
1The Kirby Institute, Sydney, New South Wales, Australia; 2Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; 3Goethe-Universität Frankfurt am Main, Germany; 4Gilead Sciences, Inc., Foster City, California, USA;
5Networked Biomedical Research Center for Hepatic and Digestive Diseases, August Pi i Sunyer Biomedical Research Institute, Hospital Clínic de Barcelona, Spain; 6Ospedale Casa Sollievo della Sofferenza, Istituto di Ricovero e Cura a Carattere Scientifico, San Giovanni Rotondo, Italy